Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes

被引：0
|
作者：
Zytnick, Deena
Woolley, Ryan
Bruns, Michelle
Shay, Christina M.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-143-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
143-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
    Busch, Robert S.
    Kane, Michael P.
    POSTGRADUATE MEDICINE, 2017, 129 (07) : 686 - 697
  • [32] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Cardoso, Pedro
    Young, Katie G.
    Nair, Anand T. N.
    Hopkins, Rhian
    Mcgovern, Andrew P.
    Haider, Eram
    Karunaratne, Piyumanga
    Donnelly, Louise
    Mateen, Bilal A.
    Sattar, Naveed
    Holman, Rury R.
    Bowden, Jack
    Hattersley, Andrew T.
    Pearson, Ewan R.
    Jones, Angus G.
    Shields, Beverley M.
    McKinley, Trevelyan J.
    Dennis, John M.
    DIABETOLOGIA, 2024, 67 (05) : 822 - 836
  • [33] A synergistic duo : Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor therapy in the management of Type 2 Diabetes
    O'Connor, T.
    Griffin, S.
    Moore, K.
    Woods, C.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S244 - S244
  • [34] Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
    Kunal K. Jha
    Rishav Adhikari
    Erfan Tasdighi
    Ngozi Osuji
    Tanuja Rajan
    Michael J. Blaha
    Current Atherosclerosis Reports, 2022, 24 : 925 - 937
  • [35] Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits
    Dixon, Dave L.
    Salgado, Teresa M.
    Robinson, Amanda
    Carbone, Salvatore
    Wagner, Tyler D.
    Hyder, Haroon
    Kirschner, Bryan
    Musselman, Kerri T.
    Buffington, Tonya M.
    Sabo, Roy T.
    MAYO CLINIC PROCEEDINGS, 2025, 100 (04) : 647 - 656
  • [36] Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits
    Lambert, Natalie
    Clark, Callahan
    McCoy, Rozalina G.
    Wong, Alyssa
    Cook, David J.
    DIABETES, 2022, 71
  • [37] Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
    Clemmensen, K. K. B.
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S29 - S29
  • [38] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [39] Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Clemmensen, K. K. B.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S30 - S30
  • [40] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
12345